vs

Side-by-side financial comparison of CIRRUS LOGIC, INC. (CRUS) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $580.6M, roughly 1.1× CIRRUS LOGIC, INC.). Royalty Pharma plc runs the higher net margin — 34.4% vs 24.2%, a 10.3% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 4.5%). Over the past eight quarters, CIRRUS LOGIC, INC.'s revenue compounded faster (25.0% CAGR vs 4.6%).

Cirrus Logic Inc. is an American fabless semiconductor supplier that specializes in analog, mixed-signal, and audio DSP integrated circuits (ICs). Since 1998, the company's headquarters have been in Austin, Texas.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

CRUS vs RPRX — Head-to-Head

Bigger by revenue
RPRX
RPRX
1.1× larger
RPRX
$622.0M
$580.6M
CRUS
Growing faster (revenue YoY)
RPRX
RPRX
+0.3% gap
RPRX
4.8%
4.5%
CRUS
Higher net margin
RPRX
RPRX
10.3% more per $
RPRX
34.4%
24.2%
CRUS
Faster 2-yr revenue CAGR
CRUS
CRUS
Annualised
CRUS
25.0%
4.6%
RPRX

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
CRUS
CRUS
RPRX
RPRX
Revenue
$580.6M
$622.0M
Net Profit
$140.3M
$214.2M
Gross Margin
53.1%
Operating Margin
26.3%
62.4%
Net Margin
24.2%
34.4%
Revenue YoY
4.5%
4.8%
Net Profit YoY
21.0%
2.9%
EPS (diluted)
$2.66
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRUS
CRUS
RPRX
RPRX
Q4 25
$580.6M
$622.0M
Q3 25
$561.0M
$609.3M
Q2 25
$407.3M
$578.7M
Q1 25
$424.5M
$568.2M
Q4 24
$555.7M
$593.6M
Q3 24
$541.9M
$564.7M
Q2 24
$374.0M
$537.3M
Q1 24
$371.8M
$568.0M
Net Profit
CRUS
CRUS
RPRX
RPRX
Q4 25
$140.3M
$214.2M
Q3 25
$131.6M
$288.2M
Q2 25
$60.7M
$30.2M
Q1 25
$71.3M
$238.3M
Q4 24
$116.0M
$208.2M
Q3 24
$102.1M
$544.0M
Q2 24
$42.1M
$102.0M
Q1 24
$44.8M
$4.8M
Gross Margin
CRUS
CRUS
RPRX
RPRX
Q4 25
53.1%
Q3 25
52.5%
Q2 25
52.6%
Q1 25
53.4%
Q4 24
53.6%
Q3 24
52.2%
Q2 24
50.5%
Q1 24
51.8%
Operating Margin
CRUS
CRUS
RPRX
RPRX
Q4 25
26.3%
62.4%
Q3 25
25.8%
70.1%
Q2 25
17.8%
36.3%
Q1 25
20.2%
94.0%
Q4 24
26.2%
60.9%
Q3 24
24.3%
Q2 24
12.5%
50.2%
Q1 24
14.1%
-13.0%
Net Margin
CRUS
CRUS
RPRX
RPRX
Q4 25
24.2%
34.4%
Q3 25
23.5%
47.3%
Q2 25
14.9%
5.2%
Q1 25
16.8%
41.9%
Q4 24
20.9%
35.1%
Q3 24
18.8%
96.3%
Q2 24
11.3%
19.0%
Q1 24
12.1%
0.8%
EPS (diluted)
CRUS
CRUS
RPRX
RPRX
Q4 25
$2.66
$0.49
Q3 25
$2.48
$0.67
Q2 25
$1.14
$0.07
Q1 25
$1.30
$0.55
Q4 24
$2.11
$0.46
Q3 24
$1.83
$1.21
Q2 24
$0.76
$0.23
Q1 24
$0.78
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRUS
CRUS
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$778.1M
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$2.1B
$9.7B
Total Assets
$2.5B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRUS
CRUS
RPRX
RPRX
Q4 25
$778.1M
$618.7M
Q3 25
$593.5M
$938.9M
Q2 25
$548.9M
$631.9M
Q1 25
$539.6M
$1.1B
Q4 24
$526.4M
$929.0M
Q3 24
$445.8M
$950.1M
Q2 24
$491.4M
$1.8B
Q1 24
$502.8M
$843.0M
Total Debt
CRUS
CRUS
RPRX
RPRX
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
CRUS
CRUS
RPRX
RPRX
Q4 25
$2.1B
$9.7B
Q3 25
$2.0B
$9.6B
Q2 25
$1.9B
$9.5B
Q1 25
$1.9B
$9.8B
Q4 24
$2.0B
$10.3B
Q3 24
$1.9B
$10.3B
Q2 24
$1.8B
$9.8B
Q1 24
$1.8B
$9.9B
Total Assets
CRUS
CRUS
RPRX
RPRX
Q4 25
$2.5B
$19.6B
Q3 25
$2.4B
$19.3B
Q2 25
$2.3B
$18.3B
Q1 25
$2.3B
$17.6B
Q4 24
$2.4B
$18.2B
Q3 24
$2.4B
$18.0B
Q2 24
$2.3B
$17.7B
Q1 24
$2.2B
$16.1B
Debt / Equity
CRUS
CRUS
RPRX
RPRX
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRUS
CRUS
RPRX
RPRX
Operating Cash FlowLast quarter
$290.8M
$827.1M
Free Cash FlowOCF − Capex
$285.7M
FCF MarginFCF / Revenue
49.2%
Capex IntensityCapex / Revenue
0.9%
Cash ConversionOCF / Net Profit
2.07×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$614.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRUS
CRUS
RPRX
RPRX
Q4 25
$290.8M
$827.1M
Q3 25
$92.2M
$702.6M
Q2 25
$116.1M
$364.0M
Q1 25
$130.4M
$596.1M
Q4 24
$218.6M
$742.5M
Q3 24
$8.2M
$703.6M
Q2 24
$87.2M
$658.2M
Q1 24
$170.5M
$664.6M
Free Cash Flow
CRUS
CRUS
RPRX
RPRX
Q4 25
$285.7M
Q3 25
$88.3M
Q2 25
$113.5M
Q1 25
$127.0M
Q4 24
$211.9M
Q3 24
$5.6M
Q2 24
$77.2M
Q1 24
$163.5M
FCF Margin
CRUS
CRUS
RPRX
RPRX
Q4 25
49.2%
Q3 25
15.7%
Q2 25
27.9%
Q1 25
29.9%
Q4 24
38.1%
Q3 24
1.0%
Q2 24
20.6%
Q1 24
44.0%
Capex Intensity
CRUS
CRUS
RPRX
RPRX
Q4 25
0.9%
Q3 25
0.7%
Q2 25
0.6%
Q1 25
0.8%
Q4 24
1.2%
Q3 24
0.5%
Q2 24
2.7%
Q1 24
1.9%
Cash Conversion
CRUS
CRUS
RPRX
RPRX
Q4 25
2.07×
3.86×
Q3 25
0.70×
2.44×
Q2 25
1.91×
12.06×
Q1 25
1.83×
2.50×
Q4 24
1.88×
3.57×
Q3 24
0.08×
1.29×
Q2 24
2.07×
6.45×
Q1 24
3.80×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRUS
CRUS

Audio Products Segment$344.5M59%
High Performance Mixed Signal Products$236.2M41%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons